We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $633M
1-Year Est. Return 173.22%
This Fund
S&P 500
This Quarter Est. Return
-0.43%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$277M
AUM Growth
-$111M
Cap. Flow
-$85.4M
Cap. Flow %
-30.81%
Top 10 Hldgs %
98.86%
Holding
22
New
6
Increased
5
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
STOK icon
Stoke Therapeutics
STOK
+$20.1M
2
CCCC icon
C4 Therapeutics
CCCC
+$19.4M
3
CGEM icon
Cullinan Oncology
CGEM
+$8.03M
4
GHRS icon
GH Research
GHRS
+$7.88M
5
ALLO icon
Allogene Therapeutics
ALLO
+$6.57M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$89.3M
2
CABA icon
Cabaletta Bio
CABA
+$19.5M
3
MRUS
Merus
MRUS
+$14.6M
4
SLN
Silence Therapeutics
SLN
+$11.4M
5
AUTL
Autolus Therapeutics
AUTL
+$8.87M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$71.4M 25.76%
1,206,707
-302,300
-20% -$14.6M
STOK icon
2
Stoke Therapeutics
STOK
$1.82B
$70.1M 25.27%
5,185,191
+1,488,371
+40% +$20.1M
GHRS icon
3
GH Research
GHRS
$1.87B
$46.3M 16.69%
3,966,726
+656,163
+20% +$7.88M
CCCC icon
4
C4 Therapeutics
CCCC
$376M
$31.8M 11.47%
6,880,527
+3,245,865
+89% +$19.4M
TCRX icon
5
TScan Therapeutics
TCRX
$51.9M
$30.6M 11.03%
5,224,600
– –
CGEM icon
6
Cullinan Oncology
CGEM
$1.05B
$6.58M 2.37%
+377,323
New +$8.03M
ALLO icon
7
Allogene Therapeutics
ALLO
$601M
$5.19M 1.87%
+2,228,295
New +$6.57M
LBPH
8
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$4.52M 1.63%
+167,317
New +$3.3M
PASG icon
9
Passage Bio
PASG
$15.9M
$4.02M 1.45%
252,881
+10,587
+4% +$259K
CABA icon
10
Cabaletta Bio
CABA
$439M
$3.68M 1.33%
492,103
-1,590,870
-76% -$19.5M
IBIO icon
11
iBio
IBIO
$71M
$1.77M 0.64%
840,763
+240,763
+40% +$518K
NEUP
12
Neuphoria Therapeutics
NEUP
$19.7M
$460K 0.17%
49,973
-17,899
-26% -$195K
PVLA
13
Palvella Therapeutics
PVLA
$1.98B
$427K 0.15%
43,499
-66,241
-60% -$747K
KNSA icon
14
Kiniksa Pharmaceuticals
KNSA
$4.83B
$177K 0.06%
+9,500
New +$178K
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$157K 0.06%
17,400
– –
KRRO icon
16
Korro Bio
KRRO
$153M
$129K 0.05%
+3,800
New +$210K
VYNE icon
17
VYNE Therapeutics
VYNE
$340K
$31.9K 0.01%
+16,194
New +$40.4K
AUTL
18
Autolus Therapeutics
AUTL
$386M
– –
-1,390,160
Closed -$8.87M
NKTR icon
19
Nektar Therapeutics
NKTR
$2.39B
– –
-137,923
Closed -$1.93M
SLN
20
Silence Therapeutics
SLN
$521M
– –
-526,642
Closed -$11.4M
ALPN
21
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-2,253,183
Closed -$89.3M
KNTE
22
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-1,981,106
Closed -$5.27M

Similar funds

SWM
SilverOak Wealth Management Edina, Minnesota $632M AUM 18.6% 1-Year Est. Return
RFA
Rollins Financial Advisors New York City, New York $632M AUM 23.84% 1-Year Est. Return
WA
WFM Asia Road Town, Tortola, British Virgin Islands $632M AUM 14.51% 1-Year Est. Return
AMM
American Money Management Rancho Santa Fe, California $632M AUM 14.06% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $634M AUM
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return

Lynx1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Lynx1 Capital Management held 22 positions worth $277M, down 29% from $388M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Lynx1 Capital Management withdrew a net $85.4M in Q2 2024, closing 5 positions and reducing 4 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $89.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Lynx1 Capital Management opened a new position in Cullinan Oncology worth $6.58M.

  • Lynx1 Capital Management's largest Q2 2024 buy was Cullinan Oncology: 377,323 shares worth $6.58M.
  • Lynx1 Capital Management added most to Stoke Therapeutics in Q2 2024, an estimated $20.1M increase.
  • Lynx1 Capital Management's biggest Q2 2024 reduction was Cabaletta Bio, cutting an estimated $19.5M.
  • Lynx1 Capital Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $89.3M.
  • Lynx1 Capital Management's ten largest holdings make up 99% of its $277M portfolio in Q2 2024.
  • Lynx1 Capital Management opened 6 new positions and closed 5 in Q2 2024.
  • Lynx1 Capital Management's portfolio value fell 29% quarter-over-quarter to $277M.

Based on Lynx1 Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.